PARP7-IN-22 

PARP7-IN-22 (XLY-1) is a PARP7 inhibitor with an IC₅₀ of 0.6 nM. PARP7-IN-22 (XLY-1) is orally active, enhances type I interferon signaling in vitro, restores type I interferon signaling, promotes T cell infiltration into tumor tissues, and significantly inhibits tumor growth. PARP7-IN-22 shows promise for research in the field of cancer immunotherapy^[1].

PARP7-IN-22 (XLY-1) (5μM-20μM, 14 days) demonstrates no substantial influence on the activity of CT26 cells^[1].
PARP7-IN-22 (49 nM-4000 nM, 72 h) significantly enhances the expression of IFN-β and CXCL10, as well as the phosphorylation of STAT1, in a dose-dependent manner ^[1].
PARP7-IN-22 (49 nM-4000 nM, 72 h) administration exhibites a noticeable increase in TBK1 phosphorylation^[1].
PARP7-IN-22 (49 nM-4000 nM, 72 h) effectively promotes the type I interferon signaling cascade, thereby exerting anti-tumor effects^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PARP7-IN-22 (XLY-1) (Male rats, 5 mg/kg, i.v.; 30 mg/kg, p.o; 0.5-24 h) can be administered orally for further in vivo pharmacodynamic studies^[1].
PARP7-IN-22 (CT26 syngeneic model, 25 or 50 mg/kg, p.o., 14 days) demonstrates excellent anti-tumor proliferative effects in the CT26 syngeneic model ^[1].
PARP7-IN-22 (CT26 syngeneic model, 50 mg/kg, p.o., 14 days) promotes T cell infiltration into tumor tissues and exhibits targeted effects^[1].

Pharmacokinetic Analysis in CT26 Syngeneic Model^[1]

药代动力学分析^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

508.42

C₁₉H₂₂F₆N₈O₂

O=C1NN=CC(NCCCCNC(N2CCN(CC2)C3=NC=C(C=N3)C(F)(F)F)=O)=C1C(F)(F)F

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yang J, et al. Discovery of highly potent PARP7 inhibitors for cancer immunotherapy[J]. Bioorganic Chemistry, 2024, 148: 107469.  [Content Brief]